Virtual Library
Start Your Search
Y. Zhang
Author of
-
+
P2.03b - Poster Session with Presenters Present (ID 465)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.03b-051 - TrxR1: A Novel Biomarker Proved to Be Prognostic Factor and Evidence to Provide Newly Treatment Strategies in Metastatic EGFR Wild-Type NSCLC (ID 3950)
14:30 - 14:30 | Author(s): Y. Zhang
- Abstract
Background:
Figure 1Deregulating cellular energetics is one promising hallmark of cancer and Thioredoxin reductases 1 (TrxR1) plays a key role in cell metabolism [1-4]. It was found in our previous study that the activity of TrxR1 in serum is significantly higher in cancer patients than volunteers (table1, based on 1122 cancer patients VS 84 volunteers). However, the role of TrxR1 in prognosis and evaluation of treatment in EGFR wildtype non-small cell lung cancer need to be investigated.
Methods:
In cohort one, serum level of TrxR1 in 127 metastatic EGFR wide type NSCLC patients was measured by ELISA assay before receiving first line standard doublet chemotherapy( wiht PP and GP included). In cohort two, a phase IC clinical trial was conducted to compare the TrxR1 inhibitor (BBSKE) and placebo in advanced NSCLC patients with EGFR wild type mutation and high activity level of TrxR1 after second line treatment. Patients in cohorts one and two were from NCT01980212, NCT01991418 and NCT02166242. Survival data were collected in cohort one and two.
Results:
Survival data analysis in cohort one showed that the PFS of lower TrxR1 activity group was significantly long compared to the higher in the total (mPFS:5.0m vs 3.1m, p=0.029), and also in adeno subtype and squamous subtype. The same tendency was observed in OS(mOS:15.0m vs 12.5m),but the date were not mature yet. Results in cohorts two show that patients with high level activity of TrxR1 can benefit more from BBSKE( data were not matue).
Conclusion:
Human with high level TrxR1 may have the high risk to suffer from NSCLC. High level of TrxR1 may suggest poor prognosis in metastatic EGFR wild-type non-small-cell lung cancer patients. Further clinical studies are warranted to profile TrxR1 inhibitors from bench to bedside.
